Neurogene Inc. (NGNE) 10-Year Financial Performance & Capital Metrics

NGNE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutNeurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.Show more

Revenue $925K
EBITDA -$79M -51.8%
Net Income -$75M -106.9%
EPS (Diluted) -4.28 -51.2%
Gross Margin -251.03%
EBITDA Margin -8579.24%
Operating Margin -8930.27%
Net Margin -8123.68%
ROE -30.28% -18.6%
ROIC -51.57% +53.4%
Debt/Equity 0.04 -54.2%
Interest Coverage -6883.75 -48.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 37.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM1.34%

ROCE

10Y Avg-33.67%

5Y Avg-37.12%

3Y Avg-42.35%

Latest-31.76%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	7.89B	272.13	90.71	473.02%	53.3%	17.48%	1.51%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.09B	57.71	26.11	17.97%	16.82%	8.59%	4.29%	0.11
SRPTSarepta Therapeutics, Inc.	2.22B	21.14	9.03	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.35B	24.37	-3.87	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.46	-5.18			-61.26%		0.04
BEAMBeam Therapeutics Inc.	3.42B	33.69	-7.36	-83.18%	-7.44%	-42.92%		0.22
TVTXTravere Therapeutics, Inc.	3.05B	34.10	-8.36	60.55%	-20.32%	-120.36%		6.80
SLNOSoleno Therapeutics, Inc.	2.23B	41.54	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	25M	0	0	0	0	0	925K
Revenue Growth %	-	-	-	-	-1%	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	340K	1.82M	42.26M	3.2M	3.26M	3.25M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	3.51%
Gross Profit+	0	0	0	25M	-340K	-1.82M	-42.26M	-3.2M	-3.26M	-2.32M
Gross Margin %	-	-	-	1%	-	-	-	-	-	-2.51%
Gross Profit Growth %	1%	-	-	-	-1.01%	-4.36%	-22.21%	0.92%	-0.02%	0.29%
Operating Expenses+	21.34M	37.65M	51.12M	48.52M	24.1M	39.73M	8.27M	53.32M	52.32M	80.28M
OpEx % of Revenue	-	-	-	1.94%	-	-	-	-	-	86.79%
Selling, General & Admin	5.54M	9.26M	14.85M	15.73M	17.79M	15.39M	8.27M	9.01M	11.19M	22.61M
SG&A % of Revenue	-	-	-	0.63%	-	-	-	-	-	24.45%
Research & Development	15.8M	28.38M	36.27M	32.79M	6.32M	24.34M	42.26M	47.51M	44.39M	60.92M
R&D % of Revenue	-	-	-	1.31%	-	-	-	-	-	65.86%
Other Operating Expenses	0	0	0	0	0	0	-42.26M	-3.2M	-3.26M	-3.25M
Operating Income+	-21.34M	-37.65M	-51.12M	-23.52M	-24.44M	-41.55M	-50.53M	-56.52M	-55.58M	-82.61M
Operating Margin %	-	-	-	-0.94%	-	-	-	-	-	-89.3%
Operating Income Growth %	0.05%	-0.76%	-0.36%	0.54%	-0.04%	-0.7%	-0.22%	-0.12%	0.02%	-0.49%
EBITDA+	-21.76M	-37M	-50.18M	-31.58M	-24.1M	-39.73M	-49.59M	-53.32M	-52.29M	-79.36M
EBITDA Margin %	-	-	-	-1.26%	-	-	-	-	-	-85.79%
EBITDA Growth %	0.02%	-0.7%	-0.36%	0.37%	0.24%	-0.65%	-0.25%	-0.08%	0.02%	-0.52%
D&A (Non-Cash Add-back)	-421K	0	0	0	340K	1.82M	947K	3.2M	3.3M	3.25M
EBIT	-21.76M	-37M	-50.18M	-31.58M	-69.44M	-33.28M	-50.53M	-55.19M	-55.58M	-75.13M
Net Interest Income+	-99K	618K	994K	1.56M	1.54M	490K	19K	1.33M	2.94M	8.46M
Interest Income	0	619K	998K	1.56M	1.54M	490K	19K	1.34M	2.95M	8.47M
Interest Expense	99K	1K	4K	4K	1K	0	0	2K	12K	12K
Other Income/Expense	-520K	643K	936K	-8.06M	-45M	8.28M	17K	1.33M	19.27M	7.46M
Pretax Income+	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Pretax Margin %	-	-	-	-1.26%	-	-	-	-	-	-81.24%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Net Margin %	-	-	-	-1.26%	-	-	-	-	-	-81.24%
Net Income Growth %	0.08%	-0.69%	-0.36%	0.37%	-1.2%	0.52%	-0.52%	-0.09%	0.34%	-1.07%
Net Income (Continuing)	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.73	-1.96	-2.14	-1.34	-2.57	-0.64	-0.92	-4.30	-2.83	-4.28
EPS Growth %	0.37%	-0.13%	-0.09%	0.37%	-0.92%	0.75%	-0.44%	-3.67%	0.34%	-0.51%
EPS (Basic)	-1.73	-1.96	-2.14	-1.34	-2.57	-0.64	-0.92	-4.30	-2.83	-4.28
Diluted Shares Outstanding	12.64M	18.89M	23.45M	23.52M	27.03M	51.83M	55.04M	12.82M	12.82M	17.57M
Basic Shares Outstanding	12.64M	18.89M	23.45M	23.52M	27.03M	51.83M	55.04M	12.82M	12.82M	17.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	74.8M	103.48M	108.83M	77.17M	143.6M	194.52M	73.96M	84.72M	200.35M	315.92M
Cash & Short-Term Investments	74.48M	103.06M	108.08M	76.93M	143.09M	192.56M	70.54M	82.02M	197.16M	312.4M
Cash Only	39.53M	32.3M	52.03M	76.93M	143.09M	192.56M	70.54M	82.02M	148.21M	136.59M
Short-Term Investments	34.96M	70.76M	56.05M	0	0	0	0	0	48.95M	175.82M
Accounts Receivable	32K	0	0	0	0	0	790K	0	600K	648K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	255.7
Inventory	0	0	0	0	0	0	1.91M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	16.52	-	-	-
Other Current Assets	282K	426K	740K	237K	503K	1.97M	-1.2M	1.62M	1.09M	981K
Total Non-Current Assets+	38.55M	50.9M	1.5M	453K	3.43M	16M	27.53M	24.55M	22.23M	19.81M
Property, Plant & Equipment	89K	849K	905K	400K	2.83M	13.72M	27.53M	24.55M	20.95M	18.49M
Fixed Asset Turnover	-	-	-	62.50x	-	-	-	-	-	0.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	567K	347K	128K	0	0	0
Long-Term Investments	38.46M	50.05M	0	0	0	0	878K	0	0	0
Other Non-Current Assets	0	0	599K	53K	30K	1.93M	-1.01M	0	1.27M	1.31M
Total Assets+	113.34M	154.38M	110.33M	77.62M	147.02M	210.52M	101.49M	109.27M	222.57M	335.73M
Asset Turnover	-	-	-	0.32x	-	-	-	-	-	0.00x
Asset Growth %	1.74%	0.36%	-0.29%	-0.3%	0.89%	0.43%	-0.52%	0.08%	1.04%	0.51%
Total Current Liabilities+	4.79M	9.52M	10.96M	4.63M	4.74M	7.89M	10.86M	6.65M	22.97M	15.16M
Accounts Payable	0	0	0	702K	1.6M	1.32M	5.63M	625K	2.6M	1.34M
Days Payables Outstanding	-	-	-	-	1.72K	265.18	48.62	71.38	290.48	150.18
Short-Term Debt	0	0	0	0	618K	708K	1.22M	0	0	3M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.31M	8.49M	9.4M	3.92M	1.28M	2.61M	132K	167K	6.71M	1.43M
Current Ratio	15.61x	10.87x	9.93x	16.68x	30.28x	24.66x	6.81x	12.74x	8.72x	20.84x
Quick Ratio	15.61x	10.87x	9.93x	16.68x	30.28x	24.66x	6.64x	12.74x	8.72x	20.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	131K	197K	486K	319K	593K	11.41M	182.51M	3.99M	13.58M	10.2M
Long-Term Debt	124K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	7K	47K	33K	6K	593K	11.41M	4.6M	3.99M	13.37M	9.43M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	-1	0	0	177.91M	0	203K	769K
Total Liabilities	4.92M	9.72M	11.44M	4.95M	5.34M	19.3M	193.36M	10.64M	36.55M	25.36M
Total Debt+	131K	47K	33K	6K	1.21M	12.12M	6.43M	4.69M	16.25M	12.43M
Net Debt	-39.4M	-32.25M	-52M	-76.92M	-141.88M	-180.43M	-64.11M	-77.33M	-131.96M	-124.16M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.01x	0.06x	-	0.05x	0.09x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-215.56x	-37645.00x	-12779.75x	-5881.00x	-24443.00x	-	-	-28258.50x	-4631.92x	-6883.75x
Total Equity+	108.42M	144.66M	98.89M	72.67M	141.69M	191.22M	-91.88M	98.63M	186.02M	310.38M
Equity Growth %	2%	0.33%	-0.32%	-0.27%	0.95%	0.35%	-1.48%	2.07%	0.89%	0.67%
Book Value per Share	8.58	7.66	4.22	3.09	5.24	3.69	-1.67	7.69	14.51	17.67
Total Shareholders' Equity	108.42M	144.66M	98.89M	72.67M	141.69M	191.22M	-91.88M	98.63M	186.02M	310.38M
Common Stock	0	0	0	0	0	0	1K	0	0	0
Retained Earnings	-111.28M	-148.28M	-198.5M	-230.09M	-299.53M	-332.81M	-95.65M	-150.84M	-187.15M	-262.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-290K	-169K	-70K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.27M	-30.23M	-44.72M	-31.58M	-15.39M	-24.57M	-46.4M	-52.82M	-51.42M	-70.6M
Operating CF Margin %	-	-	-	-1.26%	-	-	-	-	-	-76.33%
Operating CF Growth %	-0.14%	-0.49%	-0.48%	0.29%	0.51%	-0.6%	-0.89%	-0.14%	0.03%	-0.37%
Net Income	-21.86M	-37M	-50.18M	-31.59M	-8.1M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Depreciation & Amortization	0	0	0	0	340K	1.82M	947K	3.2M	3.3M	3.25M
Stock-Based Compensation	0	0	0	0	0	0	896K	1.25M	1.42M	8.32M
Deferred Taxes	0	0	0	0	0	0	0	0	-105K	0
Other Non-Cash Items	2.14M	2.07M	4.55M	5.44M	-5.68M	5.92M	679K	608K	-15.69M	-1.06M
Working Capital Changes	-546K	4.71M	917K	-5.43M	-1.95M	966K	1.59M	-2.69M	-4.02M	-5.96M
Change in Receivables	34K	0	0	0	290K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	2.98M	-3.61M	667K	-77K
Cash from Investing+	-47.53M	-48.06M	64.01M	55.95M	-688K	-2.22M	-18.37M	-2.23M	25.64M	-125.26M
Capital Expenditures	-27K	-713K	-494K	-49K	-879K	-2.22M	-18.37M	-2.23M	-321K	-808K
CapEx % of Revenue	-	-	-	0%	-	-	-	-	-	0.87%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	20.96M	0
Cash from Financing+	92.95M	71.11M	423K	570K	82.24M	77.14M	51.06M	66.53M	92.48M	184.07M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	287K	73K	168K	-5.47M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.3M	-30.94M	-45.21M	-31.63M	-16.27M	-26.79M	-64.77M	-55.05M	-51.74M	-71.41M
FCF Margin %	-	-	-	-1.27%	-	-	-	-	-	-77.2%
FCF Growth %	-0.13%	-0.52%	-0.46%	0.3%	0.49%	-0.65%	-1.42%	0.15%	0.06%	-0.38%
FCF per Share	-1.61	-1.64	-1.93	-1.34	-0.60	-0.52	-1.18	-4.29	-4.03	-4.07
FCF Conversion (FCF/Net Income)	0.93x	0.82x	0.89x	1.00x	0.22x	0.74x	0.92x	0.96x	1.42x	0.94x
Interest Paid	0	0	0	0	0	0	0	2K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.24%	-29.24%	-41.21%	-36.82%	-64.79%	-19.99%	-101.7%	-1634.75%	-25.52%	-30.28%
Return on Invested Capital (ROIC)	-35.43%	-31.12%	-48.14%	-82.76%	-	-588.75%	-	-	-110.63%	-51.57%
Gross Margin	-	-	-	100%	-	-	-	-	-	-251.03%
Net Margin	-	-	-	-126.34%	-	-	-	-	-	-8123.68%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.01x	0.06x	-	0.05x	0.09x	0.04x
Interest Coverage	-215.56x	-37645.00x	-12779.75x	-5881.00x	-24443.00x	-	-	-28258.50x	-4631.92x	-6883.75x
FCF Conversion	0.93x	0.82x	0.89x	1.00x	0.22x	0.74x	0.92x	0.96x	1.42x	0.94x
Revenue Growth	-	-	-	-	-100%	-	-	-	-	-

Revenue by Segment

	2024
Reportable	925K
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Neurogene Inc. (NGNE) reported $0.9M in revenue for fiscal year 2024.

Neurogene Inc. (NGNE) grew revenue by 0.0% over the past year. Growth has been modest.

Neurogene Inc. (NGNE) reported a net loss of $85.1M for fiscal year 2024.

Dividend & Returns

Neurogene Inc. (NGNE) has a return on equity (ROE) of -30.3%. Negative ROE indicates the company is unprofitable.

Neurogene Inc. (NGNE) had negative free cash flow of $78.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Neurogene Inc. (NGNE) 10-Year Financial Performance & Capital Metrics

NGNE • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $925K
EBITDA -$79M -51.8%
Net Income -$75M -106.9%
EPS (Diluted) -4.28 -51.2%
Gross Margin -251.03%
EBITDA Margin -8579.24%
Operating Margin -8930.27%
Net Margin -8123.68%
ROE -30.28% -18.6%
ROIC -51.57% +53.4%
Debt/Equity 0.04 -54.2%
Interest Coverage -6883.75 -48.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 37.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM1.34%

ROCE

10Y Avg-33.67%

5Y Avg-37.12%

3Y Avg-42.35%

Latest-31.76%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	7.89B	272.13	90.71	473.02%	53.3%	17.48%	1.51%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.09B	57.71	26.11	17.97%	16.82%	8.59%	4.29%	0.11
SRPTSarepta Therapeutics, Inc.	2.22B	21.14	9.03	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.35B	24.37	-3.87	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.87B	17.46	-5.18			-61.26%		0.04
BEAMBeam Therapeutics Inc.	3.42B	33.69	-7.36	-83.18%	-7.44%	-42.92%		0.22
TVTXTravere Therapeutics, Inc.	3.05B	34.10	-8.36	60.55%	-20.32%	-120.36%		6.80
SLNOSoleno Therapeutics, Inc.	2.23B	41.54	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	25M	0	0	0	0	0	925K
Revenue Growth %	-	-	-	-	-1%	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	340K	1.82M	42.26M	3.2M	3.26M	3.25M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	3.51%
Gross Profit+	0	0	0	25M	-340K	-1.82M	-42.26M	-3.2M	-3.26M	-2.32M
Gross Margin %	-	-	-	1%	-	-	-	-	-	-2.51%
Gross Profit Growth %	1%	-	-	-	-1.01%	-4.36%	-22.21%	0.92%	-0.02%	0.29%
Operating Expenses+	21.34M	37.65M	51.12M	48.52M	24.1M	39.73M	8.27M	53.32M	52.32M	80.28M
OpEx % of Revenue	-	-	-	1.94%	-	-	-	-	-	86.79%
Selling, General & Admin	5.54M	9.26M	14.85M	15.73M	17.79M	15.39M	8.27M	9.01M	11.19M	22.61M
SG&A % of Revenue	-	-	-	0.63%	-	-	-	-	-	24.45%
Research & Development	15.8M	28.38M	36.27M	32.79M	6.32M	24.34M	42.26M	47.51M	44.39M	60.92M
R&D % of Revenue	-	-	-	1.31%	-	-	-	-	-	65.86%
Other Operating Expenses	0	0	0	0	0	0	-42.26M	-3.2M	-3.26M	-3.25M
Operating Income+	-21.34M	-37.65M	-51.12M	-23.52M	-24.44M	-41.55M	-50.53M	-56.52M	-55.58M	-82.61M
Operating Margin %	-	-	-	-0.94%	-	-	-	-	-	-89.3%
Operating Income Growth %	0.05%	-0.76%	-0.36%	0.54%	-0.04%	-0.7%	-0.22%	-0.12%	0.02%	-0.49%
EBITDA+	-21.76M	-37M	-50.18M	-31.58M	-24.1M	-39.73M	-49.59M	-53.32M	-52.29M	-79.36M
EBITDA Margin %	-	-	-	-1.26%	-	-	-	-	-	-85.79%
EBITDA Growth %	0.02%	-0.7%	-0.36%	0.37%	0.24%	-0.65%	-0.25%	-0.08%	0.02%	-0.52%
D&A (Non-Cash Add-back)	-421K	0	0	0	340K	1.82M	947K	3.2M	3.3M	3.25M
EBIT	-21.76M	-37M	-50.18M	-31.58M	-69.44M	-33.28M	-50.53M	-55.19M	-55.58M	-75.13M
Net Interest Income+	-99K	618K	994K	1.56M	1.54M	490K	19K	1.33M	2.94M	8.46M
Interest Income	0	619K	998K	1.56M	1.54M	490K	19K	1.34M	2.95M	8.47M
Interest Expense	99K	1K	4K	4K	1K	0	0	2K	12K	12K
Other Income/Expense	-520K	643K	936K	-8.06M	-45M	8.28M	17K	1.33M	19.27M	7.46M
Pretax Income+	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Pretax Margin %	-	-	-	-1.26%	-	-	-	-	-	-81.24%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Net Margin %	-	-	-	-1.26%	-	-	-	-	-	-81.24%
Net Income Growth %	0.08%	-0.69%	-0.36%	0.37%	-1.2%	0.52%	-0.52%	-0.09%	0.34%	-1.07%
Net Income (Continuing)	-21.86M	-37M	-50.18M	-31.59M	-69.44M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.73	-1.96	-2.14	-1.34	-2.57	-0.64	-0.92	-4.30	-2.83	-4.28
EPS Growth %	0.37%	-0.13%	-0.09%	0.37%	-0.92%	0.75%	-0.44%	-3.67%	0.34%	-0.51%
EPS (Basic)	-1.73	-1.96	-2.14	-1.34	-2.57	-0.64	-0.92	-4.30	-2.83	-4.28
Diluted Shares Outstanding	12.64M	18.89M	23.45M	23.52M	27.03M	51.83M	55.04M	12.82M	12.82M	17.57M
Basic Shares Outstanding	12.64M	18.89M	23.45M	23.52M	27.03M	51.83M	55.04M	12.82M	12.82M	17.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	74.8M	103.48M	108.83M	77.17M	143.6M	194.52M	73.96M	84.72M	200.35M	315.92M
Cash & Short-Term Investments	74.48M	103.06M	108.08M	76.93M	143.09M	192.56M	70.54M	82.02M	197.16M	312.4M
Cash Only	39.53M	32.3M	52.03M	76.93M	143.09M	192.56M	70.54M	82.02M	148.21M	136.59M
Short-Term Investments	34.96M	70.76M	56.05M	0	0	0	0	0	48.95M	175.82M
Accounts Receivable	32K	0	0	0	0	0	790K	0	600K	648K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	255.7
Inventory	0	0	0	0	0	0	1.91M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	16.52	-	-	-
Other Current Assets	282K	426K	740K	237K	503K	1.97M	-1.2M	1.62M	1.09M	981K
Total Non-Current Assets+	38.55M	50.9M	1.5M	453K	3.43M	16M	27.53M	24.55M	22.23M	19.81M
Property, Plant & Equipment	89K	849K	905K	400K	2.83M	13.72M	27.53M	24.55M	20.95M	18.49M
Fixed Asset Turnover	-	-	-	62.50x	-	-	-	-	-	0.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	567K	347K	128K	0	0	0
Long-Term Investments	38.46M	50.05M	0	0	0	0	878K	0	0	0
Other Non-Current Assets	0	0	599K	53K	30K	1.93M	-1.01M	0	1.27M	1.31M
Total Assets+	113.34M	154.38M	110.33M	77.62M	147.02M	210.52M	101.49M	109.27M	222.57M	335.73M
Asset Turnover	-	-	-	0.32x	-	-	-	-	-	0.00x
Asset Growth %	1.74%	0.36%	-0.29%	-0.3%	0.89%	0.43%	-0.52%	0.08%	1.04%	0.51%
Total Current Liabilities+	4.79M	9.52M	10.96M	4.63M	4.74M	7.89M	10.86M	6.65M	22.97M	15.16M
Accounts Payable	0	0	0	702K	1.6M	1.32M	5.63M	625K	2.6M	1.34M
Days Payables Outstanding	-	-	-	-	1.72K	265.18	48.62	71.38	290.48	150.18
Short-Term Debt	0	0	0	0	618K	708K	1.22M	0	0	3M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.31M	8.49M	9.4M	3.92M	1.28M	2.61M	132K	167K	6.71M	1.43M
Current Ratio	15.61x	10.87x	9.93x	16.68x	30.28x	24.66x	6.81x	12.74x	8.72x	20.84x
Quick Ratio	15.61x	10.87x	9.93x	16.68x	30.28x	24.66x	6.64x	12.74x	8.72x	20.84x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	131K	197K	486K	319K	593K	11.41M	182.51M	3.99M	13.58M	10.2M
Long-Term Debt	124K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	7K	47K	33K	6K	593K	11.41M	4.6M	3.99M	13.37M	9.43M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	-1	0	0	177.91M	0	203K	769K
Total Liabilities	4.92M	9.72M	11.44M	4.95M	5.34M	19.3M	193.36M	10.64M	36.55M	25.36M
Total Debt+	131K	47K	33K	6K	1.21M	12.12M	6.43M	4.69M	16.25M	12.43M
Net Debt	-39.4M	-32.25M	-52M	-76.92M	-141.88M	-180.43M	-64.11M	-77.33M	-131.96M	-124.16M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.01x	0.06x	-	0.05x	0.09x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-215.56x	-37645.00x	-12779.75x	-5881.00x	-24443.00x	-	-	-28258.50x	-4631.92x	-6883.75x
Total Equity+	108.42M	144.66M	98.89M	72.67M	141.69M	191.22M	-91.88M	98.63M	186.02M	310.38M
Equity Growth %	2%	0.33%	-0.32%	-0.27%	0.95%	0.35%	-1.48%	2.07%	0.89%	0.67%
Book Value per Share	8.58	7.66	4.22	3.09	5.24	3.69	-1.67	7.69	14.51	17.67
Total Shareholders' Equity	108.42M	144.66M	98.89M	72.67M	141.69M	191.22M	-91.88M	98.63M	186.02M	310.38M
Common Stock	0	0	0	0	0	0	1K	0	0	0
Retained Earnings	-111.28M	-148.28M	-198.5M	-230.09M	-299.53M	-332.81M	-95.65M	-150.84M	-187.15M	-262.3M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-290K	-169K	-70K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.27M	-30.23M	-44.72M	-31.58M	-15.39M	-24.57M	-46.4M	-52.82M	-51.42M	-70.6M
Operating CF Margin %	-	-	-	-1.26%	-	-	-	-	-	-76.33%
Operating CF Growth %	-0.14%	-0.49%	-0.48%	0.29%	0.51%	-0.6%	-0.89%	-0.14%	0.03%	-0.37%
Net Income	-21.86M	-37M	-50.18M	-31.59M	-8.1M	-33.28M	-50.52M	-55.19M	-36.32M	-75.14M
Depreciation & Amortization	0	0	0	0	340K	1.82M	947K	3.2M	3.3M	3.25M
Stock-Based Compensation	0	0	0	0	0	0	896K	1.25M	1.42M	8.32M
Deferred Taxes	0	0	0	0	0	0	0	0	-105K	0
Other Non-Cash Items	2.14M	2.07M	4.55M	5.44M	-5.68M	5.92M	679K	608K	-15.69M	-1.06M
Working Capital Changes	-546K	4.71M	917K	-5.43M	-1.95M	966K	1.59M	-2.69M	-4.02M	-5.96M
Change in Receivables	34K	0	0	0	290K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	2.98M	-3.61M	667K	-77K
Cash from Investing+	-47.53M	-48.06M	64.01M	55.95M	-688K	-2.22M	-18.37M	-2.23M	25.64M	-125.26M
Capital Expenditures	-27K	-713K	-494K	-49K	-879K	-2.22M	-18.37M	-2.23M	-321K	-808K
CapEx % of Revenue	-	-	-	0%	-	-	-	-	-	0.87%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	20.96M	0
Cash from Financing+	92.95M	71.11M	423K	570K	82.24M	77.14M	51.06M	66.53M	92.48M	184.07M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	287K	73K	168K	-5.47M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-20.3M	-30.94M	-45.21M	-31.63M	-16.27M	-26.79M	-64.77M	-55.05M	-51.74M	-71.41M
FCF Margin %	-	-	-	-1.27%	-	-	-	-	-	-77.2%
FCF Growth %	-0.13%	-0.52%	-0.46%	0.3%	0.49%	-0.65%	-1.42%	0.15%	0.06%	-0.38%
FCF per Share	-1.61	-1.64	-1.93	-1.34	-0.60	-0.52	-1.18	-4.29	-4.03	-4.07
FCF Conversion (FCF/Net Income)	0.93x	0.82x	0.89x	1.00x	0.22x	0.74x	0.92x	0.96x	1.42x	0.94x
Interest Paid	0	0	0	0	0	0	0	2K	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-30.24%	-29.24%	-41.21%	-36.82%	-64.79%	-19.99%	-101.7%	-1634.75%	-25.52%	-30.28%
Return on Invested Capital (ROIC)	-35.43%	-31.12%	-48.14%	-82.76%	-	-588.75%	-	-	-110.63%	-51.57%
Gross Margin	-	-	-	100%	-	-	-	-	-	-251.03%
Net Margin	-	-	-	-126.34%	-	-	-	-	-	-8123.68%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.01x	0.06x	-	0.05x	0.09x	0.04x
Interest Coverage	-215.56x	-37645.00x	-12779.75x	-5881.00x	-24443.00x	-	-	-28258.50x	-4631.92x	-6883.75x
FCF Conversion	0.93x	0.82x	0.89x	1.00x	0.22x	0.74x	0.92x	0.96x	1.42x	0.94x
Revenue Growth	-	-	-	-	-100%	-	-	-	-	-

Revenue by Segment

	2024
Reportable	925K
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Neurogene Inc. (NGNE) reported $0.9M in revenue for fiscal year 2024.

Neurogene Inc. (NGNE) grew revenue by 0.0% over the past year. Growth has been modest.

Neurogene Inc. (NGNE) reported a net loss of $85.1M for fiscal year 2024.

Dividend & Returns

Neurogene Inc. (NGNE) has a return on equity (ROE) of -30.3%. Negative ROE indicates the company is unprofitable.

Neurogene Inc. (NGNE) had negative free cash flow of $78.6M in fiscal year 2024, likely due to heavy capital investments.